Cambridge Cancer Genomics

About:

Cambridge Cancer Genomics develops precision oncology solutions to transform the way cancer patients are treated.

Website: http://ccg.ai

Twitter/X: ccgenomics

Top Investors: Y Combinator, Endure Capital, FundersClub, Soma Capital, Refactor

Description:

Cambridge Cancer Genomics develops precision oncology solutions to transform the way cancer patients are treated. Using simple blood draws, CCG shortens the time required to know whether treatment is working, buying the clinician more time to alter treatment and reduce unnecessary side effects. The technology can detect relapse earlier than standard of care, predict response to therapy, and decrease ineffective treatment regimens. Over time, CCG will be able to better predict the best therapeutic strategy for cancer patients before they even begin treatment. Cambridge Cancer Genomics was founded on 2016 and is headquartered in Cambridge, England.

Total Funding Amount:

$8.5M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Cambridge, Cambridgeshire, United Kingdom

Founded Date:

2016-01-01

Contact Email:

info(AT)ccg.ai

Founders:

Evaline Tsai, Harry Clifford, John Cassidy, Nirmesh Patel

Number of Employees:

11-50

Last Funding Date:

2018-12-31

IPO Status:

Private

Industries:

© 2025 bioDAO.ai